GRAIL, Inc. (NASDAQ: GRAL), a healthcare company focused on early cancer detection, saw its stock plummet 14.90% in after-hours trading on Tuesday following the release of its first-quarter 2025 financial results. The sharp decline came despite the company reporting a narrower-than-expected loss, as revenue fell short of analyst expectations.
For the quarter ended March 31, GRAIL reported revenue of $31.8 million, up from $26.7 million a year earlier but significantly below the $35.2 million forecast by analysts. The company's net loss narrowed to $3.10 per share, beating the expected loss of $3.99 per share. Despite the improved bottom line, investors seemed more focused on the top-line miss, triggering the sell-off.
On a positive note, GRAIL announced encouraging results from its NHS-Galleri trial, reporting positive top-line results from the prevalent screening round. The company also highlighted its strong cash position of $677.9 million, which it says provides a runway into 2028. However, these developments were overshadowed by the revenue shortfall. As GRAIL continues to develop its multi-cancer early detection tests, investors will likely keep a close eye on the company's ability to meet revenue expectations in the coming quarters.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.